

AKT is a therapeutic target in myeloproliferative neoplasms

Khan et al.

Supplemental Figure Legends

Supplemental Figure 1: MK-2206 shows no overt toxicity in healthy mice. Wild-type Balb/c mice were treated with captisol or MK-2206 at 60 mg/kg or 120 mg/kg for 2 weeks. **(A)** Liver and spleen weights. Bars depict means +/- SD, n=4. **(B, C, D)** Peripheral WBC (B), RBC (C) and platelet counts (D) from individual mice are shown. None of the differences in mean peripheral counts (red bars) were statistically significant.

Supplemental Figure 2: Body weight, RBC and platelet counts in transplanted mice treated with MK-2206. **(A, B)** Peripheral RBC (A) and platelet counts (B) of MPL^{W515L} engrafted mice treated with captisol (vehicle) or MK-2206 at 60 mg/kg or 120 mg/kg. Individual counts are shown. Differences among the groups were not significantly different. **(C)** Body weights of mice two days before treatment and after 10 days of treatment. Differences among the groups were not significantly different.







Figure S1






Figure S2